全球T细胞疗法市场规模、份额、趋势和成长分析报告（2026-2034年）

T 细胞疗法市场预计将从 2025 年的 54 亿美元成长到 2034 年的 253.1 亿美元，2026 年至 2034 年的复合年增长率为 18.72%。

由于免疫疗法的突破性进展，全球T细胞疗法市场正经历快速成长。 T细胞疗法，包括CAR-T疗法，利用人体免疫系统标靶癌细胞。骨髓恶性肿瘤率的上升是推动市场扩张的主要因素。

关键成长要素包括临床试验数量的增加以及先进治疗方法监管核准。製药和生物技术公司正大力投资于以细胞为基础的治疗创新。人们对个人化医疗日益增长的兴趣也进一步推动了需求。此外，已开发市场的支持性报销机制也正在加速这些疗法的普及。

随着固态肿瘤应用研究的不断深入，未来前景依然强劲。新兴市场对先进医疗基础设施的投资将创造新的机会。各公司正致力于提高生产扩充性并降低治疗成本。随着免疫疗法的不断发展，全球T细胞疗法市场预计将迎来显着的长期成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球T细胞疗法市场：依治疗方法类型划分

• 市场分析、洞察与预测
• CAR-T细胞疗法
• 基于T细胞受体（TCR）

第五章 全球T细胞疗法市场：依适应症划分

• 市场分析、洞察与预测
• 淋巴瘤
• 急性淋巴性白血病
• 其他的

第六章 全球T细胞疗法市场：依最终用户划分

• 市场分析、洞察与预测
• 医院
• 癌症治疗中心

第七章 全球T细胞疗法市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Gilead Sciences Inc
  • Cellectis Inc
  • Johnson & Johnson
  • Celyad Oncology
  • Immunocore Ltd
  • Autolus Therapeutics
  • Novartis AG
  • Cartesian Therapeutics Inc
  • Caribou Biosciences Inc
  • Bristol-Myers Squibb Company

The T-Cell Therapies Market size is expected to reach USD 25.31 Billion in 2034 from USD 5.40 Billion (2025) growing at a CAGR of 18.72% during 2026-2034.

The Global T-Cell Therapies Market is experiencing rapid growth due to breakthroughs in immunotherapy. T-cell therapies, including CAR-T treatments, harness the immune system to target cancer cells. Rising prevalence of hematological malignancies is supporting market expansion.

Major growth drivers include increasing clinical trials and regulatory approvals for advanced therapies. Pharmaceutical and biotech companies are investing heavily in cell-based treatment innovation. Growing focus on personalized medicine is further strengthening demand. Additionally, supportive reimbursement frameworks in developed markets are encouraging adoption.

Future prospects remain strong as research expands into solid tumor applications. Emerging markets investing in advanced healthcare infrastructure will create new opportunities. Companies are focusing on scalable manufacturing and reduced treatment costs. As immunotherapy continues to evolve, the Global T-Cell Therapies Market is expected to witness substantial long-term growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapy Type

• CAR T-Cell Therapy
• T-Cell Receptor (TCR)-Based

By Indication

• Lymphoma
• Acute Lymphocytic Leukemia
• Others

By End User

• Hospitals
• Cancer Treatment Centers

COMPANIES PROFILED

• Gilead Sciences Inc, Cellectis Inc, Johnson Johnson, Celyad Oncology, Immunocore Ltd, Autolus Therapeutics, Novartis AG, Cartesian Therapeutics Inc, Caribou Biosciences Inc, BristolMyers Squibb Company
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL T-CELL THERAPIES MARKET: BY THERAPY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapy Type
• 4.2. CAR T-Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. T-Cell Receptor (TCR)-Based Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL T-CELL THERAPIES MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Acute Lymphocytic Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL T-CELL THERAPIES MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Cancer Treatment Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL T-CELL THERAPIES MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Therapy Type
  • 7.2.2 By Indication
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Therapy Type
  • 7.3.2 By Indication
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Therapy Type
  • 7.4.2 By Indication
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Therapy Type
  • 7.5.2 By Indication
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Therapy Type
  • 7.6.2 By Indication
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL T-CELL THERAPIES INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Gilead Sciences Inc
  • 9.2.2 Cellectis Inc
  • 9.2.3 Johnson & Johnson
  • 9.2.4 Celyad Oncology
  • 9.2.5 Immunocore Ltd
  • 9.2.6 Autolus Therapeutics
  • 9.2.7 Novartis AG
  • 9.2.8 Cartesian Therapeutics Inc
  • 9.2.9 Caribou Biosciences Inc
  • 9.2.10 Bristol-Myers Squibb Company